Abstract:C/EBPβ overexpression exacerbates the pathologic progression of AD, primarily by promoting neuroinflammation and mediating transcriptional regulation of several disease‐associated proteins, such as δ‐secretase and APOE4. Additionally, C/EBPβ stimulates the upregulation of ANP32A and TRPC1, leading to elevated levels of phosphorylated Tau, while inhibiting the expression of FOXO, which is associated with genes involved in longevity. The in‐depth research of the pathway through which C/EBPβ regulates the development of AD also reveals multiple vicious cycle pathways between C/EBPβ overexpression and the pathological progression of AD. Background Alzheimer's disease (AD) is a neurodegenerative disorder distinguished by a swift cognitive deterioration accompanied by distinctive pathological hallmarks such as extracellular Aβ (β‐amyloid) peptides, neuronal neurofibrillary tangles (NFTs), sustained neuroinflammation, and synaptic degeneration. The elevated frequency of AD cases and its proclivity to manifest at a younger age present a pressing challenge in the quest for novel therapeutic interventions. Numerous investigations have substantiated the involvement of C/EBPβ in the progression of AD pathology, thus indicating its potential as a therapeutic target for AD treatment. Aims Several studies have demonstrated an elevation in the expression level of C/EBPβ among individuals afflicted with AD. Consequently, this review predominantly delves into the association between C/EBPβ expression and the pathological progression of Alzheimer's disease, elucidating its underlying molecular mechanism, and pointing out the possibility that C/EBPβ can be a new therapeutic target for AD. Methods A systematic literature search was performed across multiple databases, including PubMed, Google Scholar, and so on, utilizing predetermined keywords and MeSH terms, without temporal constraints. The inclusion criteria encompassed diverse study designs, such as experimental, case–control, and cohort studies, restricted to publications in the English language, while conference abstracts and unpublished sources were excluded. Results Overexpression of C/EBPβ exacerbates the pathological features of AD, primarily by promoting neuroinflammation and mediating the transcriptional regulation of key molecular pathways, including δ‐secretase, apolipoprotein E4 (APOE4), acidic leucine‐rich nuclear phosphoprotein‐32A (ANP32A), transient receptor potential channel 1 (TRPC1), and Forkhead BoxO (FOXO). Discussion The correlation between overexpression of C/EBPβ and the pathological development of AD, along with its molecular mechanisms, is evident. Investigating the pathways through which C/EBPβ regulates the development of AD reveals numerous multiple vicious cycle pathways exacerbating the pathological progression of the disease. Furthermore, the exacerbation of pathological progression due to C/EBPβ overexpression and its molecular mechanism is not limited to AD but also extends to other neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and multiple sclerosis (MS). Conclusion The overexpression of C/EBPβ accelerates the irreversible progression of AD pathophysiology. Additionally, C/EBPβ plays a crucial role in mediating multiple pathways linked to AD pathology, some of which engender vicious cycles, leading to the establishment of feedback mechanisms. To sum up, targeting C/EBPβ could hold promise as a therapeutic strategy not only for AD but also for other degenerative diseases.

Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates Δ-Secretase by Upregulating C/EBPβ in Alzheimer’s Disease

Deficiency of IKKβ in neurons ameliorates Alzheimer’s disease pathology in APP- and tau-transgenic mice

TrkB receptor cleavage by delta-secretase abolishes its phosphorylation of APP, aggravating Alzheimer’s disease pathologies

C/EBPβ Regulates Delta-Secretase Expression and Mediates Pathogenesis in Mouse Models of Alzheimer’s Disease

Spatiotemporal Activation Of The C/Ebp Beta/Delta-Secretase Axis Regulates The Pathogenesis Of Alzheimer'S Disease

Deficiency of IKK in neurons ameliorates Alzheimer's disease pathology in APP- and tau-transgenic mice

CCAAT-Enhancer Binding Protein-beta (C/EBPP) Regulates Deltasecretase Expression, Mediating the Pathogenesis in Alzheimer's Disease

Neurotrophic signaling deficiency exacerbates environmental risks for Alzheimer's disease pathogenesis

Δ-Secretase-cleaved Tau Stimulates Aβ Production Via Upregulating STAT1-BACE1 Signaling in Alzheimer's Disease.

[P4–126]: Δ‐secretase–cleaved TAU STIMULATES Aβ PRODUCTION VIA ACTIVATING STAT1‐BACE1 PATHWAY IN ALZHEIMER's DISEASE

C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer’s disease pathology in a mouse model

C/EBPβ/AEP signaling couples atherosclerosis to the pathogenesis of Alzheimer’s disease

Blocking GSK3β-mediated Dynamin1 Phosphorylation Enhances BDNF-dependent TrkB Endocytosis and the Protective Effects of BDNF in Neuronal and Mouse Models of Alzheimer's Disease

Delta- and Beta-Secretases Crosstalk Amplifies the Amyloidogenic Pathway in Alzheimer's Disease

Traumatic Brain Injury Triggers APP and Tau Cleavage by Delta-Secretase, Mediating Alzheimer's Disease Pathology.

BAD-mediated neuronal apoptosis and neuroinflammation contribute to Alzheimer's disease pathology

Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer’s disease

E2F1 Mediates Traumatic Brain Injury and Regulates BDNF-AS to Promote the Progression of Alzheimer's Disease

Amyloid Precursor Protein-Mediated Endocytic Pathway Disruption Induces Axonal Dysfunction and Neurodegeneration.